食道がん市場：タイプ、がん病期、治療、エンドユーザー別-2025～2030年の世界予測

食道がん市場は、2023年に149億米ドルと評価され、2024年には160億8,000万米ドルに達すると予測され、CAGR 8.26％で成長し、2030年には259億9,000万米ドルに達すると予測されています。

食道がん市場には、この攻撃的ながんに対処することを目的とした様々な診断、治療、調査方法が含まれています。食道がんは世界的にがんによる死亡原因の第6位を占めており、早期発見と効果的な治療法の進歩が必要とされているため、このセグメントは極めて重要です。その用途は、画像診断や生検などの早期診断ツールから、外科的介入、化学療法、標的治療、新たな免疫療法などの先進治療まで多岐にわたります。最終用途市場には、病院、がん治療センター、診断ラボなどが含まれます。この市場の成長は、人口の高齢化、胃食道逆流症（GERD）、バレット食道の罹患率の上昇、喫煙や飲酒を含むライフスタイルなどのリスク要因の有病率の増加によって大きく左右されます。低侵襲手術の技術的発展や個別化医療の開発も主要促進要因です。早期発見のためのバイオマーカー研究の進展や、特定の遺伝子変異を標的としたオーダーメイド治療開発の機会も存在します。細胞療法や免疫チェックポイント阻害剤など、最先端の治療法の研究開発に投資する企業は、競争優位に立つことができます。課題としては、高額な治療費、早期診断の難しさ、従来の治療法に抵抗性を示す疾患の不均一性などが挙げられます。さらに、厳しい規制基準や大規模な臨床検査の必要性が、市場への迅速な浸透を阻害する可能性があります。技術革新の焦点は、リキッドバイオプシー技術の改善と、診断精度の向上と治療計画立案のための人工知能の活用であると考えられます。市場はダイナミックで、製薬大手間の競合も激しいが、バイオテクノロジー新興企業が破壊的技術で大きく飛躍する機会もあります。共同研究パートナーシップや戦略的提携を重視することは、研究能力を高め、新しい治療法を効果的に商業化するために有益であると考えられます。

市場力学：急速に進化する食道がん市場の主要市場洞察を公開

食道がん市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 食道がんの有病率の増加とタイムリーな治療の必要性
  • 先進的食道がん診断技術の開発
  • がん研究に対する政府の取り組みと資金援助
• 市場抑制要因
  • 食道がん治療のリコール問題
• 市場機会
  • 有利な政府承認による食道がん治療の進歩
  • 標的療法と免疫療法の登場
• 市場課題
  • 治療開発の複雑さ

ポーターのファイブフォース：食道がん市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：食道がん市場における外部からの影響の把握

外部マクロ環境要因は、食道がん市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：食道がん市場における競合情勢の把握

食道がん市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：食道がん市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、食道がん市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：食道がん市場における成功への道筋を描く

食道がん市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 食道がんの有病率の増加とタイムリーな治療の必要性
    • 先進的食道がん診断技術の開発
    • がん研究に対する政府の取り組みと資金提供
  • 抑制要因
    • 食道がん医薬品の有害事象リコール
  • 機会
    • 政府の承認を得た食道がん医薬品の進歩
    • 標的療法と免疫療法の出現
  • 課題
    • 治療開発の複雑さ
• 市場セグメンテーション分析
  • タイプ：喫煙、飲酒、その他の有害な習慣による食道扁平上皮がんの有病率の高さ
  • 治療：手術前に化学療法と放射線療法を併用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 食道がん市場：タイプ別

• イントロダクション
• 食道腺がん
• 食道扁平上皮がん

第7章 食道がん市場：がん病期別

• イントロダクション
• フェーズI
• フェーズII
• フェーズIII

第8章 食道がん市場：治療別

• イントロダクション
• 化学療法
• 放射線治療
• 手術

第9章 食道がん市場：エンドユーザー別

• イントロダクション
• がん研究機関
• 診断ラボ
• 病院・クリニック

第10章 南北アメリカの食道がん市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の食道がん市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの食道がん市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • スゲマリマブと化学療法の併用が食道扁平上皮がんの治療として中国で承認
  • 中国に拠点を置くバイオテクノロジー企業が食道がん治療の承認を取得
  • Innovent、食道扁平上皮がんの第一選択治療としてシンチリマブと化学療法の併用療法を検討する第3相検査「ORIENT-15」の最終分析結果を発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Aurobindo Pharma Limited
• Bausch Health Companies Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cipla Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals PLC
• Jiangsu Hengrui Medicine Co., Ltd
• Johnson & Johnson Private Limited
• LEO Pharma A/S
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
• FIGURE 2. ESOPHAGEAL CANCER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ESOPHAGEAL CANCER MARKET DYNAMICS
• TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 190. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

The Esophageal Cancer Market was valued at USD 14.90 billion in 2023, expected to reach USD 16.08 billion in 2024, and is projected to grow at a CAGR of 8.26%, to USD 25.99 billion by 2030.

The esophageal cancer market encompasses a range of diagnostic, treatment, and research processes aimed at addressing this aggressive form of cancer. This sector is crucial as esophageal cancer is the sixth leading cause of cancer death globally, necessitating advancements in early detection and effective therapies. Its applications span from early-stage diagnostic tools, including imaging and biopsy, to advanced treatments like surgical interventions, chemotherapy, targeted therapy, and emerging immunotherapies. End-use markets include hospitals, cancer treatment centers, and diagnostic laboratories. Growth in this market is significantly influenced by an increasing prevalence of risk factors such as aging populations, rising incidence of gastroesophageal reflux disease (GERD), Barrett's esophagus, and lifestyle elements including smoking and alcohol use. Technological advancements in minimally invasive surgical procedures and the development of personalized medicine are also key growth drivers. Opportunities exist in advancing biomarker research for early detection and targeting specific genetic mutations to develop tailored treatments. Companies that invest in advanced R&D for cutting-edge treatments, including cell-based therapies and immune checkpoint inhibitors, stand to gain a competitive edge. Challenges include high treatment costs, difficulties in early diagnosis, and the heterogeneous nature of the disease making it resistant to conventional therapies. Additionally, stringent regulatory norms and requirement for extensive clinical trials can impede quick market penetration. Innovation could focus on improving liquid biopsy technologies and the use of artificial intelligence for better diagnostic accuracy and treatment planning. The market is dynamic, with strong competition among pharmaceutical giants, but also offers opportunities for biotech startups to make significant strides with disruptive technologies. Emphasizing collaborative research partnerships and strategic alliances would be beneficial to enhance research capabilities and commercialize new therapies effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Esophageal Cancer Market

The Esophageal Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of esophageal cancer and need for timely treatment
  • Development of sophisticated esophageal cancer diagnostic techniques
  • Government initiatives and funding for cancer research
• Market Restraints
  • Adverse recalls of esophageal cancer drugs
• Market Opportunities
  • Advancements in esophageal cancer medications with favorable government approvals
  • Emergence of targeted therapies and immunotherapies
• Market Challenges
  • Complexity in development of therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Esophageal Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Esophageal Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Esophageal Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Esophageal Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Esophageal Cancer Market

A detailed market share analysis in the Esophageal Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Esophageal Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Esophageal Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Esophageal Cancer Market

A strategic analysis of the Esophageal Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Esophageal Cancer Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co., Ltd, Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Esophageal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Esophageal Adenocarcinoma and Esophageal Squamous-Cell Carcinoma.
• Based on Cancer Phase, market is studied across Phase I, Phases II, and Phases III.
• Based on Treatment, market is studied across Chemotherapy, Radiotherapy, and Surgery.
• Based on End-Users, market is studied across Cancer Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of esophageal cancer and need for timely treatment
    • 5.1.1.2. Development of sophisticated esophageal cancer diagnostic techniques
    • 5.1.1.3. Government initiatives and funding for cancer research
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of esophageal cancer drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in esophageal cancer medications with favorable government approvals
    • 5.1.3.2. Emergence of targeted therapies and immunotherapies
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in development of therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
  • 5.2.2. Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Esophageal Cancer Market, by Type

• 6.1. Introduction
• 6.2. Esophageal Adenocarcinoma
• 6.3. Esophageal Squamous-Cell Carcinoma

7. Esophageal Cancer Market, by Cancer Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phases II
• 7.4. Phases III

8. Esophageal Cancer Market, by Treatment

• 8.1. Introduction
• 8.2. Chemotherapy
• 8.3. Radiotherapy
• 8.4. Surgery

9. Esophageal Cancer Market, by End-Users

• 9.1. Introduction
• 9.2. Cancer Research Institutes
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals & Clinics

10. Americas Esophageal Cancer Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Esophageal Cancer Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Esophageal Cancer Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma
  • 13.3.2. China-based biotech receives approval for esophageal cancer treatment
  • 13.3.3. Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. Astellas Pharma Inc.
• 5. AstraZeneca plc
• 6. Aurobindo Pharma Limited
• 7. Bausch Health Companies Inc.
• 8. Bayer AG
• 9. Boehringer Ingelheim GmbH
• 10. Bristol-Myers Squibb Company
• 11. Cipla Inc.
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche Ltd
• 14. GlaxoSmithKline Plc
• 15. Hikma Pharmaceuticals PLC
• 16. Jiangsu Hengrui Medicine Co., Ltd
• 17. Johnson & Johnson Private Limited
• 18. LEO Pharma A/S
• 19. Merck & Co., Inc.
• 20. Novartis AG
• 21. Otsuka Pharmaceutical Co., Ltd.
• 22. Pfizer Inc
• 23. Sanofi S.A.
• 24. Sun Pharmaceutical Industries Ltd.
• 25. Takeda Pharmaceutical Company Limited